Envestnet Asset Management Inc. Buys 4,217 Shares of Haemonetics Co. (NYSE:HAE)

Envestnet Asset Management Inc. grew its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 9.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 48,068 shares of the medical instruments supplier's stock after purchasing an additional 4,217 shares during the period. Envestnet Asset Management Inc. owned about 0.10% of Haemonetics worth $3,753,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in HAE. Whittier Trust Co. acquired a new stake in shares of Haemonetics during the 4th quarter valued at about $62,000. Parkside Financial Bank & Trust increased its position in Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 240 shares during the period. AlphaQuest LLC raised its stake in Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after purchasing an additional 1,826 shares during the last quarter. KBC Group NV lifted its stake in shares of Haemonetics by 54.6% in the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock valued at $157,000 after buying an additional 712 shares during the period. Finally, HighTower Advisors LLC grew its holdings in shares of Haemonetics by 7.8% during the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock worth $262,000 after purchasing an additional 244 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Stock Down 1.4 %

HAE stock traded down $0.92 during midday trading on Wednesday, hitting $63.05. The company's stock had a trading volume of 552,251 shares, compared to its average volume of 689,703. The company's fifty day moving average price is $62.82 and its 200 day moving average price is $71.91. Haemonetics Co. has a twelve month low of $55.30 and a twelve month high of $97.97. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The stock has a market capitalization of $3.17 billion, a P/E ratio of 24.82, a PEG ratio of 1.11 and a beta of 0.41.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, equities research analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on HAE. Needham & Company LLC decreased their price objective on Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a report on Tuesday, March 18th. Barrington Research lowered their price objective on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. StockNews.com downgraded Haemonetics from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. Bank of America lowered shares of Haemonetics from a "neutral" rating to an "underperform" rating and reduced their price objective for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. Finally, Raymond James reaffirmed a "strong-buy" rating and set a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Haemonetics has an average rating of "Moderate Buy" and a consensus target price of $101.22.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.